The programme for 2019 is currently being produced and promises to bring yet more opportunities for networking, sharing of knowledge and engaging with the leaders in the field of precision medicine.  If you would like us to inform you when the agenda is available please drop us an email emilyjones@precisionmedicineforum.com
For any enquiries about speaking opportunities please email Amanda Rafferty Amandarafferty@precisionmedicineforum.com
Programme (2018)
Benelux Precision Medicine Forum
12-13 June, Utrecht, The Netherlands

Denotes a link to the speaker's bio page.

Scroll down for the full agenda or download the programme in PDF format (updated 4/05/18).
DOWNLOAD THE PROGRAMME (309KB)
DAY 1 - Tuesday June 12, 2018
#beneluxpmf

Benelux Precision Medicine Forum is preceded by the free to attend Permides 2018 conference – Empowering Personalized Medicine through Digital Solutions. (9.00-12.30) For more information please click here

12:20 - 13:30
Registration and Networking Lunch
13:30 - 13:35
Opening Remarks
13:35 - 13:55
Improving the Delivery of Value-Based Personalized Cancer Care: Health Economics of Liquid Biopsies for Treatment Targeting and Monitoring

 Maarten J. IJzerman, PhD, Professor and Chair of Cancer Health Services Research


University of Melbourne and Victorian Comprehensive Cancer Center, Melbourne, Australia

Professor of Health Technology and Services Research, University of Twente
13:55 - 14:15
The economics of precision medicine: establishing value and paying for value
The talk will provide an overview of the issue of establishing whether precision medicines offer value for money, and particularly how value can be measured. Paula will discuss how value is currently measured and introduce new elements of value. She will then present some of the issues on paying for value, particularly in the face of uncertain evidence of effect and also the issues around reimbursement of the test vis-à-vis the treatment.

 Paula Lorgelly, Deputy Director, Office of Health Economics, Visiting Professor, Division of Cancer Studies, King’s College London

14:15 - 14:25
Healthcare Economics Q&A
14:25 - 14:45
Every Patient Counts - Making Precision Medicine a Reality for European Cancer Patients

 Ian Walker, Roche Foundation Medicine

14:45 - 15:05
National scale tumor whole genome sequencing for personalized cancer treatment in the Netherlands

 Prof. dr. Edwin Cuppen, Hartwig Medical Foundation, Amsterdam, The Netherlands

15:05 - 15:25
Bridging the innovation gap in biomarker research

Our understanding of disease mechanisms has dramatically increased over the last decades. Molecules involved in disease processes in theory can serve as precise reporters of patient’s disease status, and then are referred to as biomarkers. Yet, the speed with which biomarkers are being developed and implemented in patient care tremendously lags behind the speed at which mechanisms of disease are unraveled. This innovation gap to a large extent is caused by suboptimal logistics and infrastructure for clinical validation. Fragmentation of resources, initiatives, collections, regulations etc. is a major cause of the problem, and is due to social, cultural and organizational reasons, rather than technical. Large scale concerted actions are needed to overcome this hurdle, of which the Dutch national infrastructure for personalized medicine and health research Health-RI is a prominent example.


 Gerrit A. Meijer, MD, MD, PhD, Head, Dept. of Pathology, Netherlands Cancer Institute; Professor of Oncologic Pathology, University Medical Center Utrecht; BBMRI-NL, EATRIS-NL, Health-RI

15:25 - 15:40
Panel Discussion: Precision Oncology

 Ian Walker, Roche Foundation Medicine


 Prof. dr. Edwin Cuppen, Hartwig Medical Foundation, Amsterdam, The Netherlands


 Gerrit A. Meijer, MD, PhD, Head, Dept. of Pathology, Netherlands Cancer Institute

15:40 - 16:10
Networking Coffee Break
16:10 - 16:35
How biomarker validation platforms can complement Precision Medicine to maximize efficiency

 Dr. Catherine Larue, CEO IBBL, Luxembourg

16:35 - 17:00
The current trend for Diagnostics and PM in the Era of Big Data:
  • Overview of the leading Diagnostic technologies to drive PM
  • Current trend of big data and AI for PM, the opportunities and the challenges

 Yiu-Lian Fong, Ph.D, MBA Global Head Diagnostic Innovation, Research and Early Development, and Lab Operations, Johnson and Johnson Innovation

17:00 - 17:20
Diagnostics as a key to unlock Precision Medicine

 Bregje van Oorschot, Brand Manager Oncology AstraZeneca

17:20 - 17:45
Panel Discussion:

 Dr. Catherine Larue, CEO IBBL, Luxembourg


 Yiu-Lian Fong, Ph.D, MBA Global Head Diagnostic Innovation, Research and Early Development, and Lab Operations, Johnson and Johnson Innovation


 Bregje van Oorschot PhD, Diagnostics Manager Oncology, AstraZeneca

15:40 - 16:10
Networking Drinks Reception
DAY 2 - Wednesday June 13, 2018
#beneluxpmf
09:10 - 9.40
Clinical and Translational Sciences: 'Personalised Medicine in Europe'

 Jean-Luc Sanne, Senior Policy Officer Unit for the Innovative and Personalised Medicine Unit, Health Research Directorate in DG Research and Innovation

09:40 - 10.00
Quantifying the benefits of personalised medicines to patients, society and healthcare systems

Summary: Charles River Associates has conducted an evidence-based analysis on behalf of The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Biopharmaceutical Enterprises (EBE), to characterise and quantify the benefits of personalised medicines to patients, society and healthcare systems. This study seeks to identify barriers and enablers to the development and adoption of PM in Europe and elaborate strategic recommendations for decision-makers to overcome these barriers and incentivise the development and adoption of PM in Europe.


 Anthony Baron, Associate Principal in the Life Sciences Practice of Charles River Associates

10:00 - 10.20
Innovations in Molecular Insights in Personalized Health and Medicine

Abstract: We have reached a fantastic period in science. Exponential developments in molecular technologies including next gene sequencing and mass spectrometry have enabled us to obtain increasing insights in the molecular components of human biology and their interactions. Novel personalized diagnostics and of high precision medicines that interfere with selected disease mechanisms are now driving the new paradigm of precision medicine. Even extending our ambitions towards personalized health, we now aim to translate interdisciplinary molecular research to knowledge, understanding and actionable decisions for people to maintain and/or improve their health. We are, however, rediscovering that human physiology is a highly complex system and that we need multiple viewing angles to begin to understand the complexity and identify its key nodes. Integration of various ‘omics analysis platforms is a powerful approach towards that end.


 Alain van Gool, Professor Personalized Healthcare, Radboud University Medical Center, DTL, EATRIS, Health-RI

10:20 - 10:30
Q&A
10:30 - 11:00
Networking Coffee Break
11:00 - 11.20
A Systems Medicine approach to understand, re-classify and treat chronic inflammatory diseases in a personalized way

 Timothy Radstake MD, PhD, Professor of Translational Immunology within the departments of Rheumatology & Clinical Immunology and on the Laboratory of Translational Immunology, UMC Utrecht

11:20 - 11.40
Precision Medicine in respiratory disease

 Prof. Dr. A.H. (Anke-Hilse) Maitland-van der Zee, Professor Precision Medicine in Respiratory Disease Academisch Medisch Centrum (AMC)

11:40 - 12.00
Translational Systemics for Precision Medicine

 Prof Dr Kristel Van Steen, GIGA-R University of Liege, KU Leuven, Belgium

12:00 - 12.20
Precision Medicine – A data Enabled Reality

 Michelle Garred, Director of Marketing, Bluebee

12:20 - 13:20
Networking Lunch
13:20 - 14:30
Roundtable Sessions
14:30 - 14.50
Your DNA as a guide for Personal Drug Therapy: it is here today!

 Prof. Dr. Ron van Schaik, International Expert Center Pharmacogenetics Dept. Clinical Chemistry Erasmus University Medical Center

14:50 - 15.10
Biobanks as vehicles for researching population health

Abstract: We have reached a fantastic period in science. Exponential developments in molecular technologies including next gene sequencing and mass spectrometry have enabled us to obtain increasing insights in the molecular components of human biology and their interactions. Novel personalized diagnostics and of high precision medicines that interfere with selected disease mechanisms are now driving the new paradigm of precision medicine. Even extending our ambitions towards personalized health, we now aim to translate interdisciplinary molecular research to knowledge, understanding and actionable decisions for people to maintain and/or improve their health. We are, however, rediscovering that human physiology is a highly complex system and that we need multiple viewing angles to begin to understand the complexity and identify its key nodes. Integration of various ‘omics analysis platforms is a powerful approach towards that end.


 Cisca Wijmenga, Professor of Human Genetics, University of Groningen and University Medical Center Groningen

15:10 - 15:30
Networking Coffee
15:30 - 15.50
Personalized Medicine - but this time for real!

 Dr. h.c. Peter Kapitein, Patient Advocate Inspire2Live

15:50 - 16.10
A family physician’s vision of precision medicine in daily practice: implementing genetics effectively
  • A (pharmaco)genetics case in daily primary care practice
  • Genetic educational needs, PhD results
  • Genetics is team work
  • Genetics, Ehealth and applications in daily practice
  • Genetics education: don’t go too fast or implementation won’t take place!

 Dr. E.J.F. Houwink, Assistant Prof LUMC, General Practitioner-General Genetics in primary care

16:10 - 16.30
Panel Discussion: The Clinical Implementation of Precision Medicine
16.30
Conference Close